Permacol manufacturer TSL plans expansion with share placing
This article was originally published in Clinica
Executive Summary
UK AIM-listed medical implants company Tissue Science Laboratories late last week announced improvements in sales and results (excluding exceptional charges) for 2003 and a £2.58m ($4.8m) share placing to fund expansion of its Permacol/Pelvicol porcine dermal collagen implant products, which are sold in sheet and injectable form.